Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Earnings Data
Report Date
May 12, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.67Last Year’s EPS
-0.95Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong commercial launch and material financial progress — meaningful sequential revenue growth (~40% Q/Q), positive operating cash flow and full-year profitability — alongside encouraging commercial metrics (1,250 start forms, 859 active patients, 630 prescribers and coverage of >180M lives). Key near-term risks flagged include EU regulatory uncertainty, anticipated increases in COGS as inventory normalizes, seasonality-driven Q1 gross-to-net effects, elevated SG&A for continued launch investment, and an expected long-term discontinuation range of 15%–20%. On balance, the positive financial and commercial momentum and ample cash runway outweigh the outlined challenges.Company Guidance
Strong Revenue Growth and Profitability
Q4 net revenue of $91.7M, representing sequential growth of nearly 40% from $66.0M in Q3; full-year 2025 net revenue of $190.4M (note: <9 months of commercial sales). Achieved profitability with full-year net income of $20.9M and Q4 net income of ~$43.4M compared to a net loss in the prior-year periods.
Robust Cash Generation and Balance Sheet
Generated $48.7M of cash from operating activities in Q4 and ended the year with $506.1M of cash, cash equivalents and marketable securities (after a $100M accelerated share repurchase), providing strong capital to support U.S. launch, EU activities and new indications.
Successful Commercial Launch Metrics
Since launch through Dec 31, 2025: 1,250 patient start forms (≈12.5% of the U.S. addressable market) and 859 active patients on treatment (up from 764 at end of Q3, a ~12.4% increase quarter-over-quarter). Added 136 new prescribers in Q4 to reach 630 unique prescribers.
Broad Payer Coverage
Secured coverage across commercial, Medicaid and Medicare channels covering over 180 million lives at the end of Q4, and reimbursed claims from ~45 state Medicaid programs through Q4, supporting rapid access and reauthorization success.
Real-World Safety and Adherence
Real-world safety profile mirrors clinical expectations; launch-to-date discontinuation related to adverse events ~12% and total discontinuation ~15%, consistent with management’s long-term expectation of 15%–20%. High adherence observed as patients settle into optimal doses.
Pipeline Expansion Plans — EU and GSD1
EMA MAA validated; Day 120 questions answered and Day 180 questions expected by end of Feb; decision anticipated mid-2026. Pursuing glycogen storage disease type 1 (GSD1) with orphan designation in U.S. and EU, IND planned in H1 2026 and trial initiation later in 2026.
SLNO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SLNO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $41.01 | $38.09 | -7.12% |
Nov 04, 2025 | $63.85 | $46.87 | -26.59% |
Aug 06, 2025 | $81.19 | $78.71 | -3.05% |
May 07, 2025 | $74.66 | $76.26 | +2.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Soleno Therapeutics Inc (SLNO) report earnings?
Soleno Therapeutics Inc (SLNO) is schdueled to report earning on May 12, 2026, TBA (Confirmed).
What is Soleno Therapeutics Inc (SLNO) earnings time?
Soleno Therapeutics Inc (SLNO) earnings time is at May 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SLNO EPS forecast?
SLNO EPS forecast for the fiscal quarter 2026 (Q1) is 0.67.